within Pharmacolibrary.Drugs.ATC.S;

model S01AE09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00020666666666666666,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0132,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0195,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01AE09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tosufloxacin is a fluoroquinolone antibacterial agent primarily used for the treatment of various bacterial infections. It has broad-spectrum activity against both Gram-positive and Gram-negative organisms. While widely used in Japan for respiratory, urinary tract, and ophthalmic infections, its use is restricted or not approved in several countries (such as the US and Europe), partially due to concerns regarding adverse effects including severe toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Keating, GM (2011). Sitafloxacin: in bacterial infections. <i>Drugs</i> 71(6) 731–744. DOI:<a href=\"https://doi.org/10.2165/11207380-000000000-00000\">10.2165/11207380-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21504249/\">https://pubmed.ncbi.nlm.nih.gov/21504249</a></p></li><li><p>Sasaki, J (2000). [Azithromycin in dentistry and oral surgery]. <i>The Japanese journal of antibiotics</i> 53 Suppl B 117–124. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12572095/\">https://pubmed.ncbi.nlm.nih.gov/12572095</a></p></li><li><p>Wiesner, A, et al., &amp; Paśko, P (2024). Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses. <i>Clinical pharmacokinetics</i> 63(6) 773–818. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01377-0\">10.1007/s40262-024-01377-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38807006/\">https://pubmed.ncbi.nlm.nih.gov/38807006</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01AE09;
